NO953281L - Anvendelse av oligosakkaridglykosider som hemmere av bakteriell adherens - Google Patents

Anvendelse av oligosakkaridglykosider som hemmere av bakteriell adherens

Info

Publication number
NO953281L
NO953281L NO953281A NO953281A NO953281L NO 953281 L NO953281 L NO 953281L NO 953281 A NO953281 A NO 953281A NO 953281 A NO953281 A NO 953281A NO 953281 L NO953281 L NO 953281L
Authority
NO
Norway
Prior art keywords
gastric
oligosaccharide
inhibitors
terminal
bacterial adherence
Prior art date
Application number
NO953281A
Other languages
English (en)
Other versions
NO953281D0 (no
Inventor
Jan Staffan Normark
Per Falk
Thomas Boren
Original Assignee
Jan Staffan Normark
Per Falk
Thomas Boren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK22293A external-priority patent/DK22293D0/da
Priority claimed from DK76093A external-priority patent/DK76093D0/da
Application filed by Jan Staffan Normark, Per Falk, Thomas Boren filed Critical Jan Staffan Normark
Publication of NO953281L publication Critical patent/NO953281L/no
Publication of NO953281D0 publication Critical patent/NO953281D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Helicobater pylori har vært vurdert som en bidragende faktor i et antall patologiske tilstander, inkludert akutt (type B) gastritt, gastriske og duodenale ulkere, gastrisk adenokarcinom og gastrisk lymfom. Oppfinnelsen angår anvendelsen av di- eller oligosakkaridglykoslder som inneholder minst en terminal L-fukoseenhet for fremstilling av farmasøytiske sammensetninger for behandling eller profylakse av mennesker med en tilstand som involverer infeksjon av Helicobacter pylori i human gastrisk mukosa, så vel som en metode for å behandle slike tilstander som anvender di- eller oligosakkaridglykos der ved administrering til en pasient som har behov for dette av en effektiv mengde av et di- eller oligosakkaridglykosid som omfatter minst en terminal L-fukoseenhet.
NO953281A 1993-02-26 1995-08-21 Anvendelse av oligosakkaridglykosider som hemmere av bakteriell adherens NO953281D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK22293A DK22293D0 (da) 1993-02-26 1993-02-26 Anvendelse af glycosider
DK76093A DK76093D0 (da) 1993-06-25 1993-06-25 Anvendelse af glycosider
PCT/IB1994/000023 WO1994018986A1 (en) 1993-02-26 1994-02-25 Use of oligosaccharide glycosides as inhibitors of bacterial adherence

Publications (2)

Publication Number Publication Date
NO953281L true NO953281L (no) 1995-08-21
NO953281D0 NO953281D0 (no) 1995-08-21

Family

ID=26063555

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953281A NO953281D0 (no) 1993-02-26 1995-08-21 Anvendelse av oligosakkaridglykosider som hemmere av bakteriell adherens

Country Status (8)

Country Link
EP (1) EP0690717A1 (no)
JP (1) JPH08509467A (no)
CN (1) CN1121311A (no)
AU (1) AU6042594A (no)
CA (1) CA2157049A1 (no)
HU (1) HU9502497D0 (no)
NO (1) NO953281D0 (no)
WO (1) WO1994018986A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204431B1 (en) 1994-03-09 2001-03-20 Abbott Laboratories Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk
DE19701382A1 (de) 1997-01-16 1998-07-23 Nutricia Nv Kohlenhydratmischung
KR100460173B1 (ko) * 1998-12-11 2004-12-04 겐 코오포레이션 헬리코박터 파일로리 정착 억제제
US6630452B2 (en) 2000-02-17 2003-10-07 Wyeth Nutritional formulation containing prebiotic substances
CN1229115C (zh) * 2000-02-17 2005-11-30 惠氏公司 含有益生素物质的营养配方
ATE429233T1 (de) * 2001-06-29 2009-05-15 Glykos Finland Oy Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten
DE10147100A1 (de) * 2001-09-25 2003-04-17 Numico Res B V Antiinfektive Kohlenhydrate
US20050233307A1 (en) 2002-09-12 2005-10-20 Kyle Gee Site-specific labeling of affinity tags in fusion proteins
WO2009033011A1 (en) 2007-09-07 2009-03-12 Children's Hospital Medical Center Use of secretor, lewis and sialyl antigen levels as predictors for disease
RU2410100C2 (ru) * 2009-03-30 2011-01-27 Александр Владимирович Диковский Фармацевтическая композиция ингибитора протонной помпы и пребиотика для лечения язвенных поражений желудка и 12-перстной кишки
ES2651067T3 (es) 2009-07-06 2018-01-24 Children's Hospital Medical Center Inhibición de la inflamación con oligosacáridos de la leche
MY191538A (en) * 2010-12-31 2022-06-30 Abbott Lab Human milk oligosaccharides to promote growth of beneficial bacteria
EP2692740A1 (en) * 2012-07-30 2014-02-05 Le Centre National De La Recherche Scientifique Glycan compositions, processes for preparing the same and their uses as a drug
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
EP3288389A4 (en) 2015-04-28 2018-10-10 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain
CN111436617B (zh) * 2020-05-12 2022-12-23 西北大学 基于牛血清白蛋白的岩藻糖拟糖蛋白在抑制惰性凝集杆菌方面的用途及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935406A (en) * 1988-09-20 1990-06-19 Marion Laboratories, Inc. Use of bismuth (phosph/sulf)ated saccharides against Camplyobacter-associated gastrointestinal disorders
US5116821A (en) * 1990-11-20 1992-05-26 The Procter & Gamble Company Sulfated glyceroglucolipids as inhibitors of bacterial adherence
AU4993893A (en) * 1992-07-31 1994-03-03 Neose Pharmaceuticals, Inc. Compositions for treating and inhibiting gastric and duodenal ulcers

Also Published As

Publication number Publication date
JPH08509467A (ja) 1996-10-08
CA2157049A1 (en) 1994-09-01
CN1121311A (zh) 1996-04-24
WO1994018986A1 (en) 1994-09-01
EP0690717A1 (en) 1996-01-10
AU6042594A (en) 1994-09-14
HU9502497D0 (en) 1995-10-30
NO953281D0 (no) 1995-08-21

Similar Documents

Publication Publication Date Title
NO953281L (no) Anvendelse av oligosakkaridglykosider som hemmere av bakteriell adherens
Tytgat et al. Helicobacter pylori infection and duodenal ulcer disease
KR950007868A (ko) 항궤양제 및 헬리코박터·피롤리의 정착저해제
NO20024011L (no) Karbohydratformulering (prebiotisk hjelpemiddel) for å forbedre immunforsvaret
ATE35418T1 (de) Oligosaccharide mit selektiver, antikoagulierender wirkung.
NZ510677A (en) Use of glycogen phosphorylase inhibitors for the prophylactic treatment of type 2 diabetes mellitus
DE69916319D1 (de) Oligosaccharide und probiotica enthaltendes präparat
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
Saberi-Firoozi et al. Effect of Triple Therapy or Amoxycillin Plus Omeprazole or Amoxycillin Plus Tinidazole Plus Omeprazole on Duodenal Ulcer Healing, Eradication of Helicobacter pylori, and Prevention of Ulcer Relapse over a 1--Year Follow--Up Period: A Prospective, Randomized, Controlled Study
Sallay et al. Bacterial invasion of oral tissues of immunosuppressed rats
AU1796188A (en) Chewing gum having a controlled sweetness
CA2120062A1 (en) Use of Sulodexide and of Medicines Containing It in the Treatment of Diabetic Nephropathy
Bell et al. Eradication of Helicobacter pylori and its effect in peptic ulcer disease
EP0194794A3 (en) Saccharide digestion inhibiting composition
Hunt et al. The current role of Helicobacter pylori eradication in clinical practice
NO20005588L (no) Inhibisjon av Helicobacter Pylori proliferasjon
Sung et al. Triple Therapy with Sucralfate, Tetracycline, and Metronidazole for Helicobacter pylori--Associated Duodenal Ulcers.
Asaka et al. The role of Helicobacter pylori in peptic ulcer disease
Jorde et al. Ranitidine 150 mg at night in the prevention of gastric ulcer relapse.
ATE243521T1 (de) Verwendung von biopolymeren zur behandlung der muskeln
Catalano et al. Helicobacter pylori-Positive Functional Dyspepsia in Elderly Patients Comparison of Two Treatments
AU4155700A (en) Use of fucosylated sialylated n-acetyl lactosamine carbohydrate structures for inhibition of bacterial adherence
Kuipers et al. Helicobacter pylori, proton pump inhibitors and gastroesophageal reflux disease
NO965468L (no) Farmasöytisk preparat for forhindring og/eller behandling av virale infeksjoner og eventuelle inflammasjoner, så vel som en behandlingsmetode derfor
CA2267543A1 (en) Use of sulodexide and of the medicines containing it in the treatment of the diabetic retinopathy